The studies focused on three tumor types: non-small cell lung cancer (NSCLC) (8), urothelial carcinoma (UC) (9), and breast cancer (BC), including both triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) subtypes (7, 15, 19). This evidence concerns the gene ERBB2 and urothelial carcinoma.